Published in J Virol on June 01, 2001
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
RASMOL: biomolecular graphics for all. Trends Biochem Sci (1995) 33.76
Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A (1986) 32.58
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 26.19
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 24.69
Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 20.59
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 18.53
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 17.13
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell (1996) 14.64
The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (1998) 12.44
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol (1996) 11.91
Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. J Exp Med (1997) 11.01
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol (1999) 10.41
Biologic features of HIV-1 that correlate with virulence in the host. Science (1988) 9.06
A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science (1998) 8.36
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol (1989) 8.32
Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol (1990) 7.85
Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol (1990) 6.73
Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature (1997) 6.23
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol (1995) 5.43
Epitopes of the CD4 antigen and HIV infection. Science (1986) 4.50
Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med (1995) 4.28
Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol (2000) 3.52
Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol (1997) 3.44
CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol (1997) 3.04
Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol (1994) 2.96
HIV infection does not require endocytosis of its receptor, CD4. Cell (1988) 2.88
Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol (1997) 2.72
Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. Virology (2000) 2.60
Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol (1997) 2.51
Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol (1994) 2.51
Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1. J Virol (1998) 2.21
Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. J Virol (1999) 2.02
Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J Virol (1996) 1.94
Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity. Proc Natl Acad Sci U S A (1991) 1.76
Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Proc Natl Acad Sci U S A (1998) 1.72
MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol (1994) 1.72
Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1992) 1.71
Host-specific driving force in human immunodeficiency virus type 1 evolution in vivo. J Virol (1997) 1.63
Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J Virol (1994) 1.57
Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles. Virology (1998) 1.57
The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. J Virol (2000) 1.50
Determinants of entry cofactor utilization and tropism in a dualtropic human immunodeficiency virus type 1 primary isolate. J Virol (1998) 1.50
Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor. J Virol (1997) 1.47
Patterns of amino acid variability in NSI-like and SI-like V3 sequences and a linked change in the CD4-binding domain of the HIV-1 Env protein. Virology (1997) 1.36
Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J Immunol (1994) 1.35
Evolution of human immunodeficiency virus type 1 env sequence variation in patients with diverse rates of disease progression and T-cell function. J Virol (1997) 1.30
Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispecies. J Virol (2000) 1.21
Monoclonal antibodies to the C4 region of human immunodeficiency virus type 1 gp120: use in topological analysis of a CD4 binding site. AIDS Res Hum Retroviruses (1992) 1.20
Immunodeficiency viruses. Spoilt for choice of co-receptors. Nature (1997) 1.12
Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants. J Virol (1998) 0.97
Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera. Virology (1996) 0.96
Interaction between HIV type 1 glycoprotein 120 and CXCR4 coreceptor involves a highly conserved arginine residue in hypervariable region 3. AIDS Res Hum Retroviruses (2000) 0.79
AIDS-free survival and overall survival in HIV infection: the new CDC classification system (1993) for HIV disease and AIDS. Clin Investig (1994) 0.76
Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis (1985) 19.03
Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science (1990) 10.13
Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis (1999) 9.81
Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell (1989) 9.66
The Mouse Genome Database (MGD): integrating biology with the genome. Nucleic Acids Res (2004) 8.91
Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 8.66
Laboratory investigation of a multistate food-borne outbreak of Escherichia coli O157:H7 by using pulsed-field gel electrophoresis and phage typing. J Clin Microbiol (1994) 8.37
The Mouse Genome Database (MGD): from genes to mice--a community resource for mouse biology. Nucleic Acids Res (2005) 8.19
Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet (1986) 7.09
Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ. Cell (1996) 6.87
Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol (1990) 6.73
Expression of a Delta homologue in prospective neurons in the chick. Nature (1995) 5.73
Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1. J Virol (1990) 5.20
Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol (1997) 5.18
Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol (1991) 5.09
Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol (1999) 4.99
Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol (1988) 4.96
A nuclear cap binding protein complex involved in pre-mRNA splicing. Cell (1994) 4.56
Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science (2001) 4.25
A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med (1992) 4.05
A cap-binding protein complex mediating U snRNA export. Nature (1995) 3.89
The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion? AIDS Res Hum Retroviruses (1991) 3.78
Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol (1999) 3.66
Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol (1989) 3.59
Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A (2004) 3.57
Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS (1999) 3.51
Primary neurogenesis in Xenopus embryos regulated by a homologue of the Drosophila neurogenic gene Delta. Nature (1995) 3.39
Attachment of local health authority staff to general practices. 1. A study in three county boroughs with special reference to health visiting. Nurs Times (1968) 3.21
Actin cables and epidermal movement in embryonic wound healing. Nature (1992) 3.11
Notch signalling and the synchronization of the somite segmentation clock. Nature (2000) 2.84
Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. Virology (1998) 2.76
A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas (1996) 2.74
Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J Virol (2000) 2.71
Antibody response in primary human immunodeficiency virus infection. Lancet (1987) 2.69
The Peckham Health Centre, "PEP", and the concept of general practice during the 1930s and 1940s. Med Hist (1983) 2.65
Analysis of heterogeneous viral populations by direct DNA sequencing. Biotechniques (1993) 2.65
Subtype-specific problems with quantification of plasma HIV-1 RNA. AIDS (1997) 2.60
Regional brain and ventricular volumes in Tourette syndrome. Arch Gen Psychiatry (2001) 2.59
Pediatric telephone triage protocols: standardized decisionmaking or a false sense of security? Ann Emerg Med (1999) 2.58
Accurate reconstruction of a known HIV-1 transmission history by phylogenetic tree analysis. Proc Natl Acad Sci U S A (1996) 2.57
Community treatment of end-stage renal failure by dialysis and renal transplantation from cadaver donors. Lancet (1969) 2.53
Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol (2001) 2.50
Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers. Proc Natl Acad Sci U S A (1993) 2.49
Tempo and mode of nucleotide substitutions in gag and env gene fragments in human immunodeficiency virus type 1 populations with a known transmission history. J Virol (1997) 2.47
Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation (2001) 2.46
Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4. AIDS (1990) 2.46
Nonfatal childhood injuries: a survey at the Children's Hospital of eastern Ontario. CMAJ (1992) 2.32
The prevalence of gut translocation in humans. Gastroenterology (1994) 2.32
Codistribution of collagen types IV and AB2 in basement membranes and mesangium of the kidney. an immunoferritin study of ultrathin frozen sections. J Cell Biol (1980) 2.30
Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP. Proc Natl Acad Sci U S A (2001) 2.29
High resolution microendoscopy for classification of colorectal polyps. Endoscopy (2013) 2.29
In vitro studies of complement function in sera of C4-deficient guinea pigs. J Exp Med (1971) 2.29
Comparative audit of colorectal resection with the POSSUM scoring system. Br J Surg (1994) 2.28
Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature (1991) 2.28
Development and mapping of microsatellite (SSR) markers in wheat. Theor Appl Genet (2005) 2.27
Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J Virol (1999) 2.26
Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol (2004) 2.26
Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc Natl Acad Sci U S A (1998) 2.23
Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology (1998) 2.20
env sequences of simian immunodeficiency viruses from chimpanzees in Cameroon are strongly related to those of human immunodeficiency virus group N from the same geographic area. J Virol (2000) 2.17
Maintenance of neuroepithelial progenitor cells by Delta-Notch signalling in the embryonic chick retina. Curr Biol (1997) 2.13
Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. Antimicrob Agents Chemother (1994) 2.13
Healing of incisional wounds in the embryonic chick wing bud: characterization of the actin purse-string and demonstration of a requirement for Rho activation. J Cell Biol (1996) 2.12
Standardization and control of meningococcal vaccines, group A and group C polysaccharides. J Biol Stand (1977) 2.11
The molecular clock of HIV-1 unveiled through analysis of a known transmission history. Proc Natl Acad Sci U S A (1999) 2.11
Biological and molecular characterization of subtype D, G, and A/D recombinant HIV-1 transmissions in Sweden. Virology (1995) 2.07
Improved outcomes with endovascular stent grafts for thoracic aorta transections. Eur J Vasc Endovasc Surg (2008) 2.06
Few infected CD4+ T cells but a high proportion of replication-competent provirus copies in asymptomatic human immunodeficiency virus type 1 infection. J Virol (1991) 2.05
A mouse model for beta 0-thalassemia. Proc Natl Acad Sci U S A (1995) 2.01
Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users. Lancet (1990) 2.01
Intuitive hypertext-based molecular identification of micro-organisms. Lancet (1999) 2.01
5' splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10. J Biol Chem (1999) 2.00
High mortality of infant bacteraemia clinically indistinguishable from severe malaria. QJM (2004) 2.00
The concept of social care and the analysis of contemporary welfare states. Br J Sociol (2000) 1.99
Comparison of cation-adjusted Mueller-Hinton broth with Iso-Sensitest broth for the NCCLS broth microdilution method. J Antimicrob Chemother (2000) 1.95
Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet (2000) 1.94
New human and simian HIV-related retroviruses possess functional transactivator (tat) gene. Nature (1987) 1.93
Characterization of Chlamydia trachomatis omp1 genotypes among sexually transmitted disease patients in Sweden. J Clin Microbiol (2001) 1.90
Early ear development in the embryo of the zebrafish, Danio rerio. J Comp Neurol (1996) 1.87
Randomized trial of drainage of colorectal anastomosis. Br J Surg (1993) 1.87
Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis (1993) 1.86
Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120. Virology (1992) 1.84
Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS (1989) 1.83
CD45-null transgenic mice reveal a positive regulatory role for CD45 in early thymocyte development, in the selection of CD4+CD8+ thymocytes, and B cell maturation. J Exp Med (1996) 1.83
Controlled clinical trial of antilymphocyte globulin in patients with renal allografts from cadaver donors. Lancet (1971) 1.82
National health insurance coverage and socio-economic status in a rural district of Ghana. Trop Med Int Health (2009) 1.81
A quantitative real-time PCR assay for the identification and enumeration of Alexandrium cysts in marine sediments. Deep Sea Res Part 2 Top Stud Oceanogr (2010) 1.81
An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. AIDS (1989) 1.80
Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing. J Clin Microbiol (2001) 1.79
Effect of cost on the self-administration and efficacy of nicotine gum: a preliminary study. Prev Med (1991) 1.78
Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein. J Virol (2000) 1.76
Comparison of in-house and commercial sample preparation and PCR amplification systems for detection of human immunodeficiency virus type 1 DNA in blood samples from Tanzanian adults. J Clin Microbiol (1997) 1.76
The prevalence and prophylaxis of gout in England. J Clin Epidemiol (1995) 1.75
MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol (1994) 1.72